Forward Pharma A/S (FWP:NASDAQ) Investor Relations Material

Overview

Forward Pharma A/S is a Danish biopharmaceutical company that has been developing a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The company granted Biogen an irrevocable license to all of its intellectual property through a License Agreement and received a non-refundable cash fee of $1.25 billion in February 2017. The company then distributed a return of EUR 917.7 million to shareholders through a capital reduction in September 2017. Forward Pharma A/S may receive royalties from Biogen from their net sales of Tecfidera® or other DMF products for multiple sclerosis outside of the U.S, dependent on a favorable outcome in Europe with respect to the Opposition Proceeding, including any appeal.

Annual Reports

Frequently Asked Questions

What is Forward Pharma A/S's ticker?

Forward Pharma A/S's ticker is FWP

What exchange is Forward Pharma A/S traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Forward Pharma A/S's headquarters?

They are based in København K, Denmark

How many employees does Forward Pharma A/S have?

There are 1-10 employees working at Forward Pharma A/S

What is Forward Pharma A/S's website?

It is https://forward-pharma.com/

What type of sector is Forward Pharma A/S?

Forward Pharma A/S is in the Healthcare sector

What type of industry is Forward Pharma A/S?

Forward Pharma A/S is in the Biotechnology industry

Who are Forward Pharma A/S's peers and competitors?

The following five companies are Forward Pharma A/S's industry peers:

- OPKO Health

- Alten

- Invivo Therapeutics Holdings Corp

- Noxopharm

- Pfenex Inc